Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(17%)
Results Posted
100%(3 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_2
3
50%
Ph phase_1
3
50%

Phase Distribution

3

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
3(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(3)
Terminated(2)

Detailed Status

Completed3
Withdrawn1
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (50.0%)
Phase 23 (50.0%)

Trials by Status

withdrawn117%
active_not_recruiting117%
terminated117%
completed350%

Recent Activity

1 active trials
Showing 5 of 6
active_not_recruitingphase_2

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

NCT03069378
completedphase_2

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

NCT02819843
completedphase_1

T-VEC in Non-melanoma Skin Cancer

NCT03458117
completedphase_1

TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)

NCT03555032
terminatedphase_1

A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion

NCT03597009
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03069378Phase 2

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Active Not Recruiting
NCT02819843Phase 2

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

Completed
NCT03458117Phase 1

T-VEC in Non-melanoma Skin Cancer

Completed
NCT03555032Phase 1

TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)

Completed
NCT03597009Phase 1

A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion

Terminated
NCT03972046Phase 2

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6